Michael G. Douvas, MD
Targeted Cancer Therapy
Mike Douvas, MD, Assistant Professor of Medicine, participates in translational research. Within the preclinical realm, he is part of a multi-institution collaborative effort to develop small molecule inhibitors of the nuclear transcription factor named core binding factor as a new targeted cancer therapy. This nuclear transcription factor plays a role in the development of some forms of acute myeloid leukemia and acute lymphoblastic leukemia through a variety of mechanisms including chromosomal translocations and point mutations. Core binding factor also plays a role in the development and progression of skeletal metastases of solid tumors such as breast and prostate cancer. He collaborates here at the University of Virginia with Dr. John Bushweller, Professor of Molecular Physiology and Biological Physics, and with other researchers at Dartmouth, Harvard, and the University of Massachusetts in developing these inhibitors as potential therapeutics for patients with leukemia and solid tumors. Dr. Douvas also participates in the Hematologic Malignancy Clinical Research program headed by Dr. Michael E. Williams and is a principal and co-investigator on several clinical trials for patients with leukemia, lymphoma, and multiple myeloma. He is board certified in Adult Hematology and also Pediatric Hematology/Oncology and also serves as a co-investigator on Children's Oncology Group clinical research protocols as they pertain to the care of young adults with cancer.